Kato Tomoyuki, Nagasawa Masayuki, Tanaka Ippei, Seyama Yuka, Sekikawa Reiko, Yamada Shiori, Ishikawa Eriko, Kitajima Kento
Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan.
Department of Infection Control, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan.
Antibiotics (Basel). 2024 Sep 14;13(9):886. doi: 10.3390/antibiotics13090886.
The increase in fluoroquinolone (FQ)-resistant (EC) is a serious global problem. In addition, much of acute uncomplicated cystitis (AUC) cases are caused by EC. FQs have been selected for the treatment of cystitis in outpatients, and there is concern about treatment failure. It is therefore necessary to select appropriate antimicrobials to spare FQs. However, there are few reported effective antimicrobial stewardship programs (ASPs) for outpatients. We aimed to establish the effective ASP for outpatients diagnosed with AUC caused by EC, to spare the use of FQs, and to explore optimal oral antimicrobials for AUC. The study subjects were outpatients treated for AUC caused by extended-spectrum β-lactamase-non-producing EC (non-ESBL-EC). Based on the antibiogram results, we recommended cefaclor (CCL) as the initial treatment for AUC, and educated clinical pharmacists who also worked together to advocate for CCL or cephalexin (CEX) prescriptions. FQ usages decreased, and cephalosporin (Ceph) prescriptions increased in all medical departments. The Ceph group (n = 114; CCL = 60, CEX = 54) in the non-FQ group had fewer treatment failures than the FQ group (n = 86) (12.3% vs. 31.4%). Cephs, including CCL and CEX, were effective treatments for AUC caused by non-ESBL-EC. Antimicrobial selection based on antibiogram results and the practice of an ASP in collaboration with clinical pharmacists were useful for optimizing antimicrobial therapy in outpatients.
耐氟喹诺酮(FQ)大肠埃希菌(EC)的增加是一个严重的全球问题。此外,许多急性单纯性膀胱炎(AUC)病例由EC引起。FQ已被选用于门诊膀胱炎的治疗,人们担心治疗失败。因此,有必要选择合适的抗菌药物以节省FQ的使用。然而,针对门诊患者的有效抗菌药物管理计划(ASP)报道较少。我们旨在为诊断为EC引起的AUC的门诊患者建立有效的ASP,以节省FQ的使用,并探索AUC的最佳口服抗菌药物。研究对象是接受治疗的由产超广谱β-内酰胺酶阴性EC(非ESBL-EC)引起的AUC门诊患者。根据药敏结果,我们推荐头孢克洛(CCL)作为AUC的初始治疗药物,并对临床药师进行培训,他们也共同努力倡导使用CCL或头孢氨苄(CEX)处方。所有医疗科室的FQ使用量均下降,头孢菌素(Ceph)处方量增加。非FQ组的Ceph组(n = 114;CCL = 60,CEX = 54)治疗失败的病例少于FQ组(n = 86)(12.3%对31.4%)。包括CCL和CEX在内的Cephs是治疗非ESBL-EC引起的AUC的有效药物。基于药敏结果进行抗菌药物选择以及与临床药师合作开展ASP实践有助于优化门诊患者的抗菌治疗。